Chemours Co (CC) 8-K Current Report: March 12, 2026
Filed: March 12, 2026
Health Care
Chemicals & Allied ProductsChemours Co (CC) 8-K current report filed with SEC EDGAR on March 12, 2026. This page provides AI-powered analysis of reported events and material disclosures, including results of operations, corporate governance changes, agreements, and other triggering events as disclosed under Form 8-K item codes.
Reported 8-K Items1 item
- Item 8.01: Other Events
Chemours Co 8-K Mar 12, 2026 Event Analysis
Item 8.01 · Other Events
- • $700M in 7.875% Senior Notes due 2034 closed Mar 12, 2026 — rate significantly higher than the notes being retired
- • Proceeds used to redeem $188M of 5.750% notes due 2028 (~$189.8M total) and ~$500.3M of 5.375% notes due 2027
- • Refinancing extends maturities from 2027/2028 to 2034 but meaningfully increases interest cost (5.375–5.75% → 7.875%)
- • Change of control triggers mandatory 101% repurchase offer; equity redemption option allows up to 40% buyback at 107.875% before Mar 2029
- • Notes unsecured, unsubordinated — rank pari passu with existing unsecured debt; no new collateral pledged
Other Chemours Co 8-K Filings
Get deeper insights on Chemours Co
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.